Trials / Completed
CompletedNCT00129038
Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess whether adding modified-release dipyridamole to aspirin (Asasantin Retard) has measurable effects on markers of platelet function (for example, platelet aggregation) in patients with cardiovascular disease who are known to be resistant to aspirin alone
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | modified-release dipyridamole/aspirin | |
| DRUG | aspirin |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2007-01-01
- First posted
- 2005-08-11
- Last updated
- 2025-01-23
Locations
2 sites across 1 country: Ireland
Source: ClinicalTrials.gov record NCT00129038. Inclusion in this directory is not an endorsement.